Fig. 1

Schematic representation of the main features and limits of TAA-specific and TAA-independent adoptive immunotherapy strategies against ovarian cancer. CAR: Chimeric-antigen receptors; CIK: Cytokine-induced killer; HLA: Human leukocyte antigen; LAK: Lymphokine Activated Killer; NK: Natural killer; TAA: Tumor associated antigen; TIL: Tumor-infiltrating lymphocytes